Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK5 | Q8IW41 | 3/20 | 0.46 |
| ▸ | TTK | P33981 | 7/20 | 0.42 |
| ▸ | FYN | P06241 | 1/20 | 0.42 |
| ▸ | MC4R | P32245 | 1/20 | 0.42 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.41 |
| ▸ | BRAF | P15056 | 1/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.40 |
| ▸ | MTOR | P42345 | 1/20 | 0.40 |
| ▸ | AURKA | O14965 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 3/20 | 0.39 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30372085 | 1.00 | MAPKAPK5 (0.46) | MAPKAPK5TTKFYNMC4RPTK6 | |
| SCHEMBL24105262 | 0.92 | PTK6 (0.45) | MAPKAPK5TTKFYNMC4RPTK6 | |
| SCHEMBL30168164 | 0.91 | FYN (0.52) | MAPKAPK5TTKFYNPTK6AURKA | |
| SCHEMBL24105240 | 0.91 | FYN (0.52) | MAPKAPK5TTKFYNPTK6AURKA | |
| SCHEMBL30168210 | 0.91 | FYN (0.45) | MAPKAPK5TTKFYNPTK6 | |
| SCHEMBL24104803 | 0.89 | TTK (0.46) | MAPKAPK5TTKFYNMC4RPTK6 | |
| SCHEMBL30168183 | 0.89 | TTK (0.46) | MAPKAPK5TTKFYNMC4RPTK6 | |
| SCHEMBL24105256 | 0.86 | IDO1 (0.41) | MAPKAPK5TTKFYNPTK6BRAF | |
| SCHEMBL30371633 | 0.86 | IDO1 (0.41) | MAPKAPK5TTKFYNPTK6BRAF | |
| SCHEMBL24104678 | 0.85 | TTK (0.44) | MAPKAPK5TTKFYNMC4RPTK6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230141403-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230141403-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-05-11 | — | — | US | disclosed |
| WO-2021249893-A1 | NOVEL IMIDAZO-PYRAZINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2021-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230141403-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | XDH, MYD88, IKZF3 | MAPKAPK5 771/4885TTK 4157/4885FYN 3892/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.